Hydrocortisone

Identification

Name

Hydrocortisone

Accession Number

DB00741  (APRD01019, DB07886)

Type

Small Molecule

Groups

Approved, Vet approved

Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00741 (Hydrocortisone)

×

Close

Synonyms

• (11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
• 11beta-hydrocortisone
• 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
• 11β-hydrocortisone
• 17-Hydroxycorticosterone
• 4-pregnen-11β,17α,21-triol-3,20-dione
• Cortisol
• Hidrocortisona
• Hydrocortisonum
• Kendall's compound F
• Reichstein's substance M

External IDs

NSC-10483

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
A-hydrocort Inj 1000mg/8ml	Powder, for solution	1 g	Intramuscular; Intravenous	Hospira, Inc.	1993-12-31	2012-08-03
A-hydrocort Inj 100mg/2ml	Powder, for solution	100 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
A-hydrocort Inj 250mg/2ml	Powder, for solution	250 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
A-hydrocort Inj 500mg/4ml	Powder, for solution	500 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
Aquacort Lotion 2.5%	Lotion	2.5 %	Topical	Merit Industries Inc.	1992-12-31	2002-05-14
Barriere HC 1%	Cream; Jelly	1 %	Topical	Allen & Hanburys A Glaxo Canada Ltd. Co.	1979-12-31	1998-07-29
Cortate Crm 1%	Cream	10 mg	Topical	Schering Plough	1980-12-31	2013-07-31
Cortate Ont 1%	Ointment	10 mg	Topical	Schering Plough	1980-12-31	2013-07-31
Cortef	Tablet	5 mg/1	Oral	Pharmacia & Upjohn Inc	1952-12-15	Not applicable
Cortef	Tablet	20 mg/1	Oral	Pharmacia & Upjohn Inc	1952-12-15	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Alacort	Cream	10 mg/g	Topical	Crown Laboratories	1973-03-09	Not applicable
Alacort	Cream	25 mg/g	Topical	Crown Laboratories	1973-03-09	Not applicable
Anusol HC	Cream	25 mg/g	Topical	Salix Pharmaceuticals	1984-06-06	Not applicable
Colocort	Suspension	100 mg/60mL	Rectal	Paddock Laboratories, Inc.	1999-12-31	Not applicable
Home PapKit	Cream	25 mg/g	Topical	International Brand Management, Llc	2016-09-15	Not applicable
Hydrocortisone	Tablet	20 mg/1	Oral	West Ward Pharmaceutical	1973-06-18	Not applicable
Hydrocortisone	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1973-06-18	Not applicable
Hydrocortisone	Cream	10 mg/g	Topical	Actavis Pharma Company	2002-01-03	Not applicable
Hydrocortisone	Cream	10 mg/g	Topical	ANI Pharmaceuticals, Inc.	2016-04-01	Not applicable
Hydrocortisone	Tablet	10 mg/1	Oral	Lineage Therapeutics	2007-03-30	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
1% Hydrocortisone	Cream	1 g/100g	Topical	Yuyao Jessie Commodity Co.,Ltd.	2015-12-01	Not applicable
999 Itch Relieving	Ointment	1 g/100g	Topical	Guangdong CR. Shunfeng Pharmaceutical Co Ltd	1989-07-20	Not applicable
999 Itch Relieving	Ointment	1 g/100g	Topical	Guangdong CR. Shunfeng Pharmaceutical Co Ltd	1989-07-20	Not applicable
Advanced Hydrocortisone	Cream	10 mg/g	Topical	Ultra Seal Corporation	2011-04-05	Not applicable
Ana Cool Rapid Soothing Cooling Formula	Cream	10 mg/g	Topical	Ana Cool, Llc	2015-11-25	Not applicable
Anti Itch	Lotion	1 g/100g	Topical	Walgreen	2012-03-27	Not applicable
Anti Itch	Ointment	1 g/100g	Topical	Rite Aid	2005-07-25	Not applicable
Anti Itch	Cream	1 g/100g	Topical	Safeway	2005-08-24	Not applicable
Anti Itch	Cream	1 g/100g	Topical	Hyvee	2015-11-01	Not applicable
Anti Itch	Cream	1 g/100g	Topical	Rite Aid	2013-09-11	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Acetasol HC	Hydrocortisone (1.1 g/100mL) + Acetic acid (2.41 g/100mL)	Solution	Auricular (otic)	Actavis Pharma Company	2002-09-10	Not applicable
Antibiotic Ear (Neo/Polym/HC)	Hydrocortisone (10 mg/mL) + Neomycin sulfate (3.5 mg/mL) + Polymyxin B Sulfate (10000 [USP'U]/mL)	Solution / drops	Auricular (otic)	Physicians Total Care, Inc.	1995-12-29	Not applicable
Calmurid HC Crm	Hydrocortisone (10 mg) + Urea (100 mg)	Cream	Topical	Galderma	1994-12-31	2000-08-02
Cipro	Hydrocortisone (10 mg/1mL) + Benzyl alcohol (9 mg/1mL) + Ciprofloxacin hydrochloride (2 mg/1mL)	Suspension	Auricular (otic)	Physicians Total Care, Inc.	2009-02-12	Not applicable
Cipro HC	Hydrocortisone (10 mg/mL) + Ciprofloxacin hydrochloride (2 mg/mL)	Suspension	Auricular (otic)	Alcon, Inc.	1999-03-15	Not applicable
Cipro HC	Hydrocortisone (10 mg/mL) + Benzyl alcohol (9 mg/mL) + Ciprofloxacin (2 mg/mL)	Suspension	Auricular (otic)	Stat Rx USA	1998-02-10	2018-02-08
Cipro HC	Hydrocortisone (10 mg/mL) + Ciprofloxacin hydrochloride (2 mg/mL)	Suspension	Auricular (otic)	A S Medication Solutions	1999-03-15	2017-06-20
Cipro HC Otic Suspension	Hydrocortisone (10 mg) + Ciprofloxacin (2 mg)	Suspension	Auricular (otic)	Alcon, Inc.	1999-06-22	2008-12-08
Cortisporin	Hydrocortisone (10 mg) + Bacitracin zinc (400 unit) + Neomycin sulfate (5 mg) + Polymyxin B Sulfate (10000 unit)	Ointment	Ophthalmic	Glaxosmithkline Inc	1989-12-31	2002-07-31
Cortisporin	Hydrocortisone (10 mg) + Bacitracin (400 unit) + Neomycin (5 mg) + Polymyxin B Sulfate (5000 unit)	Ointment	Topical	Glaxosmithkline Inc	1986-12-31	2014-11-03

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Ala Quin	Hydrocortisone (5 mg/g) + Clioquinol (30 mg/g)	Cream	Topical	Crown Laboratories	1970-08-19	Not applicable
Alcortin	Hydrocortisone (2 g/100g) + Diiodohydroxyquinoline (1 g/100g)	Gel	Topical	Primus Pharmaceuticals	2003-07-25	Not applicable
Cortane-B	Hydrocortisone (10 mg/mL) + Chloroxylenol (1 mg/mL) + Pramoxine hydrochloride (10 mg/mL)	Lotion	Topical	Blansett Pharmacal Co	2017-03-20	Not applicable
Dermazene	Hydrocortisone (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)	Cream	Topical	Stratus Pharmaceuticals	2001-06-11	Not applicable
Dr. Throwers Hydrotet	Hydrocortisone (1 g/100g) + Tretinoin (.05 g/100g)	Cream	Topical	Dr. Thrower's Skincare, Inc.	2015-05-15	Not applicable
FIRST Dukes Mouthwash Compounding	Hydrocortisone + Diphenhydramine hydrochloride + Nystatin	Kit	Oral	Cutis Pharma, Inc.	2010-12-15	2017-10-04
FIRST Marys Mouthwash Compounding	Hydrocortisone + Diphenhydramine hydrochloride + Nystatin + Tetracycline hydrochloride	Kit	Oral	Cutis Pharma, Inc.	2010-12-15	2017-10-04
Hydrocortisone	Hydrocortisone (1 g/100mL)	Shampoo	Topical	Dr Marder Skincare Llc	2017-06-14	Not applicable
hydrocortisone Iodoquinol	Hydrocortisone (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)	Cream	Topical	Perrigo New York Inc.	2008-07-14	Not applicable
Pramoxine-HC	Hydrocortisone (10 mg/mL) + Chloroxylenol (1 mg/mL) + Pramoxine hydrochloride (10 mg/mL)	Solution / drops	Auricular (otic)	Ascend Laboratories, LLC	2011-09-26	2016-04-05

International/Other Brands

Acticort / Aeroseb HC / Ala-Scalp / Algicirtis / Aquanil HC / Beta-HC / Cetacort / Cortaid / Delacort / Ficortril / Genacort / Glycort / Komed HC / Lacticare HC / Lubricort / Medicort / Meusicort / Micort-HC / Mildison / Nogenic HC / Nutracort / Nystaform-HC / Otocort / Penecort / Permicort / Polcort H / Preparation H Hydrocortisone Cream / Prepcort / Prevex HC / Proctocort / Proctocream / Protocort / Remederm HC / Sanatison / Scalpicin Capilar / Schericur / Sigmacort / Synacort / Systral Hydrocort / Timocort

Categories

• 11-Hydroxycorticosteroids
• 17-Hydroxycorticosteroids
• Adrenal Cortex Hormones
• Adrenals
• Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
• Alimentary Tract and Metabolism
• Anti-Inflammatory Agents
• Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
• Cardiovascular System
• Corticosteroids
• Corticosteroids Acting Locally
• Corticosteroids for Local Oral Treatment
• Corticosteroids for Systemic Use
• Corticosteroids for Systemic Use, Plain
• Corticosteroids, Dermatological Preparations
• Corticosteroids, Weak (Group I)
• Cytochrome P-450 CYP2C8 Inducers
• Cytochrome P-450 CYP3A Inducers
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inducers
• Cytochrome P-450 CYP3A4 Inducers (weak)
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A7 Substrates
• Cytochrome P-450 Enzyme Inducers
• Cytochrome P-450 Enzyme Inhibitors
• Dermatologicals
• Hormones
• Hormones, Hormone Substitutes, and Hormone Antagonists
• Hydroxycorticosteroids
• Hyperglycemia-Associated Agents
• Immunosuppressive Agents
• Intestinal Antiinflammatory Agents
• Nasal Preparations
• OAT3 Substrates
• Ophthalmological and Otological Preparations
• Ophthalmologicals
• Otologicals
• P-glycoprotein/ABCB1 Substrates
• Pregnanes
• Pregnenediones
• Pregnenes
• Sensory Organs
• Steroids
• Stomatological Preparations
• Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
• Vasoprotectives

UNII

WI4X0X7BPJ

CAS number

50-23-7

Weight

Average: 362.4599
Monoisotopic: 362.20932407

Chemical Formula

C₂₁H₃₀O₅

InChI Key

JYGXADMDTFJGBT-VWUMJDOOSA-N

InChI

InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

IUPAC Name

(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

Associated Conditions

• Acute Gouty Arthritis
• Allergic Rhinitis (AR)
• Allergic corneal marginal ulcers
• Ankylosing Spondylitis (AS)
• Anterior Segment Inflammation
• Aspiration Pneumonitis
• Asthma Bronchial
• Atopic Dermatitis (AD)
• Berylliosis
• Bullous dermatitis herpetiformis
• Congenital Adrenal Hyperplasia (CAH)
• Conjunctivitis, Seasonal Allergic
• Corneal Inflammation
• Crohn's Disease (CD)
• Dermatitis, Contact
• Dermatomyositis
• Dermatosis
• Drug hypersensitivity reaction
• Epicondylitis
• Erythroblastopenia
• Hypercalcemia of Malignancy
• Idiopathic Thrombocytopenic Purpura (ITP)
• Iridocyclitis
• Iritis
• Leukemia, Acute
• Leukemias
• Loeffler's syndrome
• Malignant Lymphomas
• Mycosis Fungoides (MF)
• Ophthalmia, Sympathetic
• Optic Neuritis
• Pemphigus
• Primary adrenocortical insufficiency
• Proteinuria
• Psoriatic Arthritis
• Rheumatic heart disease, unspecified
• Rheumatoid Arthritis
• Rheumatoid Arthritis, Juvenile
• Secondary adrenocortical insufficiency
• Secondary thrombocytopenia
• Serum Sickness
• Severe Seborrheic Dermatitis
• Stevens Johnson Syndrome
• Synovitis
• Systemic Lupus Erythematosus (SLE)
• Trichinosis
• Tuberculous Meningitis
• Ulcerative Colitis (UC)
• Acquired immune hemolytic anemia
• Acute Bursitis
• Acute Tenosynovitis
• Diffuse posterior uveitis
• Disseminated Pulmonary Tuberculosis
• Exfoliative erythroderma
• Fulminating Pulmonary Tuberculosis
• Non-suppurative Thyroiditis
• Severe Psoriasis
• Subacute Bursitis
• Symptomatic Sarcoidosis
• Systemic Dermatomyositis
• Varicella-zoster virus acute retinal necrosis

Pharmacodynamics

Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Human
AAnnexin A1	agonist	Human
UCorticosteroid 11-beta-dehydrogenase isozyme 2	Not Available	Human
U3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Not Available	Human

Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Volume of distribution

Not Available

Protein binding

95%

Metabolism

Primarily hepatic via CYP3A4

• Hydrocortisone
  6-beta-hydrocortisol

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life

6-8 hours

Clearance

Not Available

Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Corticosterone Methyl Oxidase II Deficiency (CMO II)	Disease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency	Disease
17-alpha-Hydroxylase Deficiency (CYP17)	Disease
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency	Disease
Corticosterone Methyl Oxidase I Deficiency (CMO I)	Disease
11-beta-Hydroxylase Deficiency (CYP11B1)	Disease
21-Hydroxylase Deficiency (CYP21)	Disease
3-beta-Hydroxysteroid Dehydrogenase Deficiency	Disease
Steroidogenesis	Metabolic
Corticotropin Activation of Cortisol Production	Signaling
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH	Disease
Apparent Mineralocorticoid Excess Syndrome	Disease
Steroidogenesis	Metabolic

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1-Testosterone	The risk or severity of edema formation can be increased when 1-Testosterone is combined with Hydrocortisone.	Experimental, Illicit, Investigational
1,10-Phenanthroline	The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone.	Experimental
16-Bromoepiandrosterone	The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Hydrocortisone.	Investigational
19-norandrostenedione	The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone.	Experimental, Illicit
1alpha-Hydroxyvitamin D5	The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Hydrocortisone.	Investigational
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with 2-Methoxyethanol.	Experimental
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrocortisone.	Investigational
4-Hydroxytestosterone	The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone.	Experimental, Illicit
5-androstenedione	The risk or severity of edema formation can be increased when 5-androstenedione is combined with Hydrocortisone.	Experimental, Illicit
9-(N-methyl-L-isoleucine)-cyclosporin A	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.	Investigational
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone.	Approved
Abediterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Abediterol.	Investigational
Abemaciclib	The serum concentration of Hydrocortisone can be increased when it is combined with Abemaciclib.	Approved, Investigational
Abetimus	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Abetimus.	Investigational
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Aceclofenac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Aceclofenac.	Approved, Investigational
Acemetacin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Acemetacin.	Approved, Experimental, Investigational
Acetaminophen	The serum concentration of Hydrocortisone can be increased when it is combined with Acetaminophen.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Withdrawn
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.	Approved, Vet Approved
Acteoside	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Acteoside.	Investigational
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Hydrocortisone.	Approved
Afatinib	The serum concentration of Hydrocortisone can be increased when it is combined with Afatinib.	Approved
Afelimomab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Afelimomab.	Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Albendazole	The serum concentration of Hydrocortisone can be increased when it is combined with Albendazole.	Approved, Vet Approved
Albiglutide	The therapeutic efficacy of Albiglutide can be decreased when used in combination with Hydrocortisone.	Approved
Alclofenac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Alclofenac.	Approved, Withdrawn
Alclometasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Alclometasone.	Approved
Alcuronium	The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Hydrocortisone.	Experimental
Aldesleukin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Aldesleukin.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Aldosterone.	Experimental, Investigational
Alectinib	The serum concentration of Hydrocortisone can be increased when it is combined with Alectinib.	Approved, Investigational
Alefacept	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Alefacept.	Approved, Investigational, Withdrawn
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone.	Approved, Investigational
Alfacalcidol	The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Almasilate	The bioavailability of Hydrocortisone can be decreased when combined with Almasilate.	Approved, Experimental
Alminoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Alminoprofen.	Experimental
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.	Approved
Aloglutamol	The bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol.	Approved
Aloxiprin	The risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone.	Experimental
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Hydrocortisone.	Approved
Aluminium	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium.	Approved, Investigational
Aluminium acetoacetate	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium acetoacetate.	Experimental
Aluminium glycinate	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium glycinate.	Experimental
Aluminium phosphate	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium phosphate.	Approved, Investigational
Aluminum hydroxide	The bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.	Approved, Investigational
Ambenonium	The therapeutic efficacy of Ambenonium can be decreased when used in combination with Hydrocortisone.	Approved
Amcinonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Amcinonide.	Approved
AMG-222	The therapeutic efficacy of AMG-222 can be decreased when used in combination with Hydrocortisone.	Investigational
Aminophenazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Aminophenazone.	Approved, Withdrawn
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.	Approved
Amiodarone	The serum concentration of Hydrocortisone can be increased when it is combined with Amiodarone.	Approved, Investigational
Amlodipine	The serum concentration of Hydrocortisone can be increased when it is combined with Amlodipine.	Approved
Amodiaquine	The serum concentration of Hydrocortisone can be increased when it is combined with Amodiaquine.	Approved, Investigational
Amoxapine	The serum concentration of Hydrocortisone can be increased when it is combined with Amoxapine.	Approved
Amphotericin B	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Amphotericin B.	Approved, Investigational
Amprenavir	The metabolism of Hydrocortisone can be decreased when combined with Amprenavir.	Approved, Investigational
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Hydrocortisone.	Approved, Investigational
Anagliptin	The therapeutic efficacy of Anagliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Hydrocortisone.	Approved
Androstenediol	The risk or severity of edema formation can be increased when Androstenediol is combined with Hydrocortisone.	Experimental, Illicit
Androstenedione	The risk or severity of edema formation can be increased when Androstenedione is combined with Hydrocortisone.	Experimental, Illicit
Annamycin	The serum concentration of Hydrocortisone can be increased when it is combined with Annamycin.	Investigational
Anthrax immune globulin human	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Hydrocortisone.	Approved
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Hydrocortisone.	Approved
Anthrax vaccine	The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Hydrocortisone.	Approved
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hydrocortisone.	Approved, Investigational
Antipyrine	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Antipyrine.	Approved, Investigational
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone.	Approved
Antrafenine	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Antrafenine.	Approved
Apalutamide	The serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apremilast	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Apremilast.	Approved, Investigational
Aprepitant	The serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant.	Approved, Investigational
Arbutamine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Arbutamine.	Approved
Arformoterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Arformoterol.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.	Approved, Investigational
Arsenic trioxide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Arsenic trioxide.	Approved, Investigational
Astemizole	The serum concentration of Hydrocortisone can be increased when it is combined with Astemizole.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Atamestane	The risk or severity of edema formation can be increased when Atamestane is combined with Hydrocortisone.	Investigational
Atazanavir	The metabolism of Hydrocortisone can be decreased when combined with Atazanavir.	Approved, Investigational
Atorvastatin	The serum concentration of Hydrocortisone can be increased when it is combined with Atorvastatin.	Approved
Atracurium	The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Hydrocortisone.	Approved, Experimental, Investigational
Atracurium besylate	The risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Hydrocortisone.	Approved
Azacitidine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Azacitidine.	Approved, Investigational
Azapropazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Azapropazone.	Withdrawn
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Hydrocortisone.	Approved
Azelastine	The serum concentration of Hydrocortisone can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Hydrocortisone can be increased when it is combined with Azithromycin.	Approved
Azosemide	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Azosemide.	Investigational
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Hydrocortisone.	Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Hydrocortisone.	Investigational
Bacillus calmette-guerin substrain danish 1331 live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Hydrocortisone.	Investigational
Bacillus calmette-guerin substrain tice live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Hydrocortisone.	Approved
Bacillus calmette-guerin substrain tice live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Hydrocortisone.	Approved
Bafilomycin A1	The serum concentration of Hydrocortisone can be increased when it is combined with Bafilomycin A1.	Experimental
Bafilomycin B1	The serum concentration of Hydrocortisone can be increased when it is combined with Bafilomycin B1.	Experimental
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrocortisone.	Investigational
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.	Approved, Investigational
Bambuterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bambuterol.	Approved, Investigational
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone.	Approved, Investigational
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Hydrocortisone.	Investigational
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydrocortisone.	Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Beclomethasone dipropionate.	Approved, Investigational
Becocalcidiol	The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone.	Investigational
Begelomab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Begelomab.	Experimental, Investigational
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Hydrocortisone.	Approved, Investigational
Belimumab	The risk or severity of adverse effects can be increased when Belimumab is combined with Hydrocortisone.	Approved
Belinostat	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Belinostat.	Approved, Investigational
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrocortisone.	Investigational
Bendamustine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bendamustine.	Approved, Investigational
Bendazac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bendazac.	Experimental
Bendroflumethiazide	Hydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benfluorex	The therapeutic efficacy of Benfluorex can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Benorilate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benorilate.	Experimental
Benoxaprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benoxaprofen.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Benzquinamide	The serum concentration of Hydrocortisone can be increased when it is combined with Benzquinamide.	Withdrawn
Benzthiazide	Hydrocortisone may increase the hypokalemic activities of Benzthiazide.	Approved
Benzydamine	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benzydamine.	Approved
Benzyl alcohol	The serum concentration of Hydrocortisone can be increased when it is combined with Benzyl alcohol.	Approved
Bepridil	The serum concentration of Hydrocortisone can be increased when it is combined with Bepridil.	Approved, Withdrawn
Besifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Besifloxacin.	Approved
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Hydrocortisone.	Approved, Vet Approved
Bevacizumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bevacizumab.	Approved, Investigational
Bexarotene	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bexarotene.	Approved, Investigational
Bicalutamide	The metabolism of Hydrocortisone can be decreased when combined with Bicalutamide.	Approved
Biricodar dicitrate	The serum concentration of Hydrocortisone can be increased when it is combined with Biricodar dicitrate.	Investigational
Bismuth subnitrate	The bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate.	Approved
Bitolterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bitolterol.	Withdrawn
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Hydrocortisone.	Approved, Investigational
Blinatumomab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Blinatumomab.	Approved, Investigational
Boceprevir	The metabolism of Hydrocortisone can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bolandiol	The risk or severity of edema formation can be increased when Bolandiol is combined with Hydrocortisone.	Experimental, Illicit
Bolasterone	The risk or severity of edema formation can be increased when Bolasterone is combined with Hydrocortisone.	Experimental, Illicit
Boldenone	The risk or severity of edema formation can be increased when Boldenone is combined with Hydrocortisone.	Illicit, Vet Approved
Bortezomib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.	Approved
Brefeldin A	The serum concentration of Hydrocortisone can be increased when it is combined with Brefeldin A.	Experimental
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Brentuximab vedotin.	Approved, Investigational
Briakinumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Briakinumab.	Investigational
Brodalumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Brodalumab.	Approved, Investigational
Bromfenac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bromfenac.	Approved
Bromocriptine	The metabolism of Bromocriptine can be decreased when combined with Hydrocortisone.	Approved, Investigational
Budesonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Budesonide.	Approved
Bufexamac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bufexamac.	Approved, Experimental
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Bumadizone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bumadizone.	Experimental
Bumetanide	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Bumetanide.	Approved
Buprenorphine	The serum concentration of Hydrocortisone can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Hydrocortisone can be increased when it is combined with Buspirone.	Approved, Investigational
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Hydrocortisone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cabazitaxel.	Approved
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Hydrocortisone.	Approved
Caffeine	The serum concentration of Hydrocortisone can be increased when it is combined with Caffeine.	Approved
Calcidiol	The therapeutic efficacy of Calcidiol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Calcipotriol	The therapeutic efficacy of Calcipotriol can be decreased when used in combination with Hydrocortisone.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.	Approved, Investigational
Calcium silicate	The bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate.	Experimental
Calusterone	The risk or severity of edema formation can be increased when Calusterone is combined with Hydrocortisone.	Experimental, Illicit
Canagliflozin	The serum concentration of Hydrocortisone can be increased when it is combined with Canagliflozin.	Approved
Canakinumab	The risk or severity of adverse effects can be increased when Canakinumab is combined with Hydrocortisone.	Approved, Investigational
Capecitabine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Capecitabine.	Approved, Investigational
Capromab pendetide	Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.	Approved
Captopril	The serum concentration of Hydrocortisone can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone.	Experimental, Investigational
Carboplatin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Carboplatin.	Approved
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrocortisone.	Experimental
Carfilzomib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Carfilzomib.	Approved, Investigational
Carmegliptin	The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Hydrocortisone.	Approved, Investigational
Carprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of Hydrocortisone can be increased when it is combined with Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Castanospermine.	Experimental
Cefoperazone	The serum concentration of Hydrocortisone can be increased when it is combined with Cefoperazone.	Approved, Investigational
Ceftriaxone	The serum concentration of Hydrocortisone can be increased when it is combined with Ceftriaxone.	Approved
Celecoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Celecoxib.	Approved, Investigational
Celiprolol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.	Approved
Certolizumab pegol	The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Hydrocortisone.	Approved
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Hydrocortisone.	Approved
Chloramphenicol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Chloramphenicol.	Approved, Vet Approved
Chlormadinone	The serum concentration of Hydrocortisone can be increased when it is combined with Chlormadinone.	Experimental
Chloroform	The serum concentration of Hydrocortisone can be increased when it is combined with Chloroform.	Vet Approved
Chlorothiazide	Hydrocortisone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Hydrocortisone can be increased when it is combined with Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Chlorprothixene	The serum concentration of Hydrocortisone can be increased when it is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorthalidone	Hydrocortisone may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholecalciferol	The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Choline magnesium trisalicylate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Choline magnesium trisalicylate.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ciclesonide.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone.	Experimental
Cimicoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Cimicoxib.	Investigational
Cinoxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ciprofloxacin.	Approved, Investigational
Cisatracurium	The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Hydrocortisone.	Approved
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydrocortisone.	Approved
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Hydrocortisone.	Approved, Investigational
Clarithromycin	The metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.	Approved
Clenbuterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Clenbuterol.	Approved, Investigational, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasol.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasol propionate.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clobetasone.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clocortolone.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone.	Approved, Investigational
Clofazimine	The serum concentration of Hydrocortisone can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Hydrocortisone can be increased when it is combined with Clomipramine.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Clonixin.	Approved
Cloprednol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cloprednol.	Experimental
Clostebol	The risk or severity of edema formation can be increased when Clostebol is combined with Hydrocortisone.	Experimental, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.	Approved
Clotrimazole	The metabolism of Hydrocortisone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The metabolism of Hydrocortisone can be decreased when combined with Cobicistat.	Approved
Colchicine	The serum concentration of Hydrocortisone can be increased when it is combined with Colchicine.	Approved
Concanamycin A	The serum concentration of Hydrocortisone can be increased when it is combined with Concanamycin A.	Experimental
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.	Approved
Corticotropin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Corticotropin.	Approved, Investigational, Vet Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cortisone acetate.	Approved, Investigational
Cortivazol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cortivazol.	Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.	Approved
Coumaphos	The therapeutic efficacy of Coumaphos can be decreased when used in combination with Hydrocortisone.	Vet Approved
Crizotinib	The serum concentration of Hydrocortisone can be increased when it is combined with Crizotinib.	Approved
Curcumin	The metabolism of Hydrocortisone can be decreased when combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	Hydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.	Experimental
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hydrocortisone.	Approved, Investigational
Cyclosporine	The risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone.	Approved, Investigational, Vet Approved
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone.	Approved, Investigational
Dabrafenib	The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dacarbazine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dacarbazine.	Approved, Investigational
Daclatasvir	The serum concentration of Hydrocortisone can be increased when it is combined with Daclatasvir.	Approved, Investigational
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone.	Investigational, Withdrawn
Dactinomycin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dactinomycin.	Approved, Investigational
Danazol	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with Danazol.	Approved
Dapagliflozin	The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocortisone.	Approved
Darunavir	The metabolism of Hydrocortisone can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone.	Approved
Decamethonium	The risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Hydrocortisone.	Approved
Decitabine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decitabine.	Approved, Investigational
Deferasirox	The serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deflazacort.	Approved, Investigational
Delavirdine	The metabolism of Hydrocortisone can be decreased when combined with Delavirdine.	Approved
Demecarium	The therapeutic efficacy of Demecarium can be decreased when used in combination with Hydrocortisone.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Denosumab.	Approved
Deoxyspergualin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deoxyspergualin.	Investigational
Dersalazine	The risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone.	Investigational
Desipramine	The serum concentration of Hydrocortisone can be increased when it is combined with Desipramine.	Approved, Investigational
Desmethylsertraline	The serum concentration of Hydrocortisone can be increased when it is combined with Desmethylsertraline.	Experimental
Desogestrel	The serum concentration of Hydrocortisone can be increased when it is combined with Desogestrel.	Approved
Desonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Desonide.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Desoximetasone.	Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexamethasone isonicotinate.	Vet Approved
Dexibuprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Dexketoprofen.	Approved, Investigational
Dexniguldipine	The serum concentration of Hydrocortisone can be increased when it is combined with Dexniguldipine.	Experimental
Dexrazoxane	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexrazoxane.	Approved, Withdrawn
Dexverapamil	The serum concentration of Hydrocortisone can be increased when it is combined with Dexverapamil.	Experimental
Dichlorvos	The therapeutic efficacy of Dichlorvos can be decreased when used in combination with Hydrocortisone.	Vet Approved
Diclofenac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Diclofenac.	Approved, Vet Approved
Dienogest	The risk or severity of edema formation can be increased when Dienogest is combined with Hydrocortisone.	Approved
Diethyl ether	The serum concentration of Hydrocortisone can be increased when it is combined with Diethyl ether.	Experimental
Difenpiramide	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Difenpiramide.	Experimental
Diflorasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Diflorasone.	Approved
Difloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Difloxacin.	Vet Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.	Approved, Investigational
Difluocortolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Difluocortolone.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Difluprednate.	Approved
Dihydroergocornine	The metabolism of Dihydroergocornine can be decreased when combined with Hydrocortisone.	Approved
Dihydroergocristine	The metabolism of Dihydroergocristine can be decreased when combined with Hydrocortisone.	Approved, Experimental
Dihydroergocryptine	The metabolism of Dihydroergocryptine can be decreased when combined with Hydrocortisone.	Experimental
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Hydrocortisone.	Approved, Investigational
Dihydrotachysterol	The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Hydrocortisone.	Approved
Diltiazem	The metabolism of Hydrocortisone can be decreased when combined with Diltiazem.	Approved, Investigational
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dimethyl fumarate.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dinutuximab.	Approved, Investigational
Dipivefrin	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Dipivefrin.	Approved
Dipyridamole	The serum concentration of Hydrocortisone can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	The therapeutic efficacy of Disopyramide can be decreased when used in combination with Hydrocortisone.	Approved
Distigmine	The therapeutic efficacy of Distigmine can be decreased when used in combination with Hydrocortisone.	Experimental
Dobutamine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Dobutamine.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Docetaxel.	Approved, Investigational
Dofequidar	The serum concentration of Hydrocortisone can be increased when it is combined with Dofequidar.	Experimental, Investigational
Donepezil	The therapeutic efficacy of Donepezil can be decreased when used in combination with Hydrocortisone.	Approved
Dovitinib	The serum concentration of Hydrocortisone can be increased when it is combined with Dovitinib.	Investigational
Doxacurium	The risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Hydrocortisone.	Approved
Doxazosin	The serum concentration of Hydrocortisone can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Hydrocortisone can be increased when it is combined with Doxepin.	Approved, Investigational
Doxercalciferol	The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Hydrocortisone.	Approved
Doxifluridine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Doxifluridine.	Investigational
Doxofylline	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Doxofylline.	Approved, Investigational
Doxorubicin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Hydrocortisone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Hydrocortisone can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Hydrocortisone can be increased when it is combined with Dronedarone.	Approved
Drospirenone	The serum concentration of Hydrocortisone can be increased when it is combined with Drospirenone.	Approved
Droxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Droxicam.	Withdrawn
Droxidopa	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Droxidopa.	Approved, Investigational
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Duloxetine	The serum concentration of Hydrocortisone can be increased when it is combined with Duloxetine.	Approved
Dutogliptin	The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Echothiophate	The therapeutic efficacy of Echothiophate can be decreased when used in combination with Hydrocortisone.	Approved
Econazole	The serum concentration of Hydrocortisone can be increased when it is combined with Econazole.	Approved
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Hydrocortisone.	Approved, Investigational
Edrophonium	The therapeutic efficacy of Edrophonium can be decreased when used in combination with Hydrocortisone.	Approved
Efalizumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Efalizumab.	Approved, Investigational
Efavirenz	The metabolism of Hydrocortisone can be decreased when combined with Efavirenz.	Approved, Investigational
Elacridar	The serum concentration of Hydrocortisone can be increased when it is combined with Elacridar.	Investigational
Eldecalcitol	The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Hydrocortisone.	Investigational
Elocalcitol	The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Hydrocortisone.	Investigational
Emopamil	The serum concentration of Hydrocortisone can be increased when it is combined with Emopamil.	Experimental
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.	Approved
Enasidenib	The serum concentration of Hydrocortisone can be increased when it is combined with Enasidenib.	Approved, Investigational
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Hydrocortisone.	Experimental
Enoxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Enoxacin.	Approved, Investigational
Enzalutamide	The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.	Approved
Ephedra	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Ephedra.	Approved, Nutraceutical, Withdrawn
Epinephrine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Epinephrine.	Approved, Vet Approved
Epirizole	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Epirizole.	Approved
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Hydrocortisone.	Approved
Epitizide	Hydrocortisone may increase the hypokalemic activities of Epitizide.	Experimental
Ergocalciferol	The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Ergoloid mesylate	The metabolism of Ergoloid mesylate can be decreased when combined with Hydrocortisone.	Approved
Ergonovine	The metabolism of Ergonovine can be decreased when combined with Hydrocortisone.	Approved
Ergotamine	The metabolism of Ergotamine can be decreased when combined with Hydrocortisone.	Approved
Eribulin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Eribulin.	Approved, Investigational
Erlotinib	The serum concentration of Hydrocortisone can be increased when it is combined with Erlotinib.	Approved, Investigational
Erythromycin	The serum concentration of Hydrocortisone can be increased when it is combined with Erythromycin.	Approved, Investigational, Vet Approved
Esomeprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Esomeprazole.	Approved, Investigational
Estradiol	The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estramustine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Estramustine.	Approved, Investigational
Etacrynic acid	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etacrynic acid.	Approved, Investigational
Etafedrine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Etafedrine.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.	Approved, Investigational
Ethenzamide	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ethenzamide.	Experimental
Ethinyl Estradiol	The serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.	Approved
Ethynodiol	The serum concentration of Hydrocortisone can be increased when it is combined with Ethynodiol.	Experimental
Ethynodiol diacetate	The serum concentration of Hydrocortisone can be increased when it is combined with Ethynodiol diacetate.	Approved
Etodolac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etofenamate.	Approved, Investigational
Etonogestrel	The serum concentration of Hydrocortisone can be increased when it is combined with Etonogestrel.	Approved, Investigational
Etoposide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Etoposide.	Approved
Etoricoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etoricoxib.	Approved, Investigational
Etravirine	The serum concentration of Hydrocortisone can be decreased when it is combined with Etravirine.	Approved
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone.	Approved
Evogliptin	The therapeutic efficacy of Evogliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Felbinac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Felbinac.	Experimental
Felodipine	The serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.	Approved, Investigational
Fenbufen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fenbufen.	Approved
Fenofibrate	The serum concentration of Hydrocortisone can be increased when it is combined with Fenofibrate.	Approved
Fenoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fenoprofen.	Approved
Fenoterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Fenoterol.	Approved, Investigational
Fentanyl	The serum concentration of Hydrocortisone can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fenthion	The therapeutic efficacy of Fenthion can be decreased when used in combination with Hydrocortisone.	Vet Approved
Fentiazac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Fentiazac.	Experimental
Feprazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Feprazone.	Experimental
Fingolimod	The risk or severity of adverse effects can be increased when Fingolimod is combined with Hydrocortisone.	Approved, Investigational
Firocoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Firocoxib.	Experimental, Vet Approved
Fleroxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Floctafenine.	Approved, Withdrawn
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Hydrocortisone.	Approved
Fluasterone	The risk or severity of edema formation can be increased when Fluasterone is combined with Hydrocortisone.	Investigational
Fluclorolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluclorolone.	Experimental
Fluconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Fluconazole.	Approved, Investigational
Flucytosine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flucytosine.	Approved, Investigational
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Hydrocortisone.	Approved
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hydrocortisone.	Approved, Investigational
Flumequine	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flunixin.	Vet Approved
Flunoxaprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flunoxaprofen.	Experimental
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocinonide.	Approved, Investigational
Fluocortin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocortin.	Experimental
Fluocortolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluorometholone.	Approved, Investigational
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone.	Approved
Fluoxetine	The serum concentration of Hydrocortisone can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Fluoxymesterone	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with Fluoxymesterone.	Approved, Illicit
Flupentixol	The serum concentration of Hydrocortisone can be increased when it is combined with Flupentixol.	Approved, Investigational, Withdrawn
Fluperolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluperolone.	Experimental
Fluphenazine	The serum concentration of Hydrocortisone can be increased when it is combined with Fluphenazine.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluprednisolone.	Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flurandrenolide.	Approved
Flurazepam	The serum concentration of Hydrocortisone can be increased when it is combined with Flurazepam.	Approved, Illicit, Investigational
Flurbiprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Flurbiprofen.	Approved, Investigational
Fluticasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone.	Approved, Experimental, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fluticasone propionate.	Approved
Fluvoxamine	The serum concentration of Hydrocortisone can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formestane	The risk or severity of edema formation can be increased when Formestane is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Formocortal	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Formocortal.	Experimental
Formoterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Formoterol.	Approved, Investigational
Fosamprenavir	The metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Furosemide	The excretion of Hydrocortisone can be decreased when combined with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.	Approved, Investigational
G17DT	The therapeutic efficacy of G17DT can be decreased when used in combination with Hydrocortisone.	Investigational
Galantamine	The therapeutic efficacy of Galantamine can be decreased when used in combination with Hydrocortisone.	Approved
Gallamine	The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Hydrocortisone.	Experimental
Gallamine Triethiodide	The risk or severity of myopathy and weakness can be increased when Gallamine Triethiodide is combined with Hydrocortisone.	Approved
Gallium nitrate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallium nitrate.	Approved, Investigational
Gallopamil	The serum concentration of Hydrocortisone can be increased when it is combined with Gallopamil.	Investigational
Garenoxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Gatifloxacin.	Approved, Investigational
Gefitinib	The serum concentration of Hydrocortisone can be increased when it is combined with Gefitinib.	Approved, Investigational
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Hydrocortisone.	Approved
Gemifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Gemifloxacin.	Approved, Investigational
Gemigliptin	The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone.	Approved, Investigational
Genistein	The serum concentration of Hydrocortisone can be increased when it is combined with Genistein.	Investigational
Gestodene	The serum concentration of Hydrocortisone can be increased when it is combined with Gestodene.	Approved, Investigational
GI-5005	The therapeutic efficacy of GI-5005 can be decreased when used in combination with Hydrocortisone.	Investigational
Ginkgo biloba	The therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Nutraceutical
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer is combined with Hydrocortisone.	Approved, Investigational
Glecaprevir	The serum concentration of Hydrocortisone can be increased when it is combined with Glecaprevir.	Approved, Investigational
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Glisoxepide	The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Hydrocortisone.	Investigational
GLPG-0492	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with GLPG-0492.	Investigational
Glyburide	The serum concentration of Hydrocortisone can be increased when it is combined with Glyburide.	Approved
Glycerin	The serum concentration of Hydrocortisone can be increased when it is combined with Glycerin.	Approved, Investigational
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone.	Approved
Glycodiazine	The therapeutic efficacy of Glycodiazine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Golimumab	The risk or severity of adverse effects can be increased when Golimumab is combined with Hydrocortisone.	Approved
Gosogliptin	The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Gramicidin D	The serum concentration of Hydrocortisone can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Guacetisal is combined with Hydrocortisone.	Experimental
Guar gum	The therapeutic efficacy of Guar gum can be decreased when used in combination with Hydrocortisone.	Experimental
Gusperimus	The risk or severity of adverse effects can be increased when Gusperimus is combined with Hydrocortisone.	Investigational
Halcinonide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Halcinonide.	Approved, Investigational, Withdrawn
Halometasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Halometasone.	Experimental
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone.	Approved
Hepatitis B Vaccine (Recombinant)	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Hydrocortisone.	Approved, Withdrawn
Hexoprenaline	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Hexoprenaline.	Approved, Withdrawn
HM-30181	The serum concentration of Hydrocortisone can be increased when it is combined with HM-30181.	Experimental
Human rabies virus immune globulin	The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone.	Approved
Huperzine A	The therapeutic efficacy of Huperzine A can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Hycanthone	The serum concentration of Hydrocortisone can be increased when it is combined with Hycanthone.	Approved, Investigational
Hydrochlorothiazide	Hydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Hydrocortisone.	Approved, Illicit
Hydrocortisone aceponate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone aceponate.	Experimental, Vet Approved
Hydrocortisone acetate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone acetate.	Approved, Vet Approved
Hydrocortisone butyrate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone butyrate.	Approved, Vet Approved
Hydrocortisone probutate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone probutate.	Approved, Vet Approved
Hydrocortisone succinate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone succinate.	Approved
Hydrocortisone valerate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydrocortisone valerate.	Approved, Vet Approved
Hydroflumethiazide	Hydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.	Approved, Investigational
Hydrotalcite	The bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.	Approved, Experimental, Investigational
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydroxychloroquine.	Approved
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hydroxyurea.	Approved
Hypericin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hypericin.	Investigational
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone.	Approved
Ibuprofen	The serum concentration of Hydrocortisone can be increased when it is combined with Ibuprofen.	Approved
Ibuproxam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ibuproxam.	Withdrawn
Icosapent	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Icosapent.	Approved, Nutraceutical
Idarubicin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Idarubicin.	Approved
Idelalisib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Idelalisib.	Approved
Ifosfamide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ifosfamide.	Approved
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Hydrocortisone.	Approved
Imidazole salicylate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Imidazole salicylate.	Experimental
Imiquimod	The risk or severity of adverse effects can be increased when Imiquimod is combined with Hydrocortisone.	Approved, Investigational
Indacaterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Indacaterol.	Approved
Indapamide	Hydrocortisone may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The metabolism of Hydrocortisone can be decreased when combined with Indinavir.	Approved
Indobufen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Indobufen.	Investigational
Indomethacin	The serum concentration of Hydrocortisone can be increased when it is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Indoprofen.	Withdrawn
Inecalcitol	The therapeutic efficacy of Inecalcitol can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Hydrocortisone.	Approved
INGN 225	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Hydrocortisone.	Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Beef	The therapeutic efficacy of Insulin Beef can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Degludec	The therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.	Approved
Insulin peglispro	The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Hydrocortisone.	Investigational
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.	Approved
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Interferon alfa-n3.	Approved, Investigational
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Interferon alfacon-1.	Approved, Investigational
Ipidacrine	The therapeutic efficacy of Ipidacrine can be decreased when used in combination with Hydrocortisone.	Experimental
Irinotecan	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Irinotecan.	Approved, Investigational
Isavuconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isoetarine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Isoetarine.	Approved
Isoflurophate	The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Withdrawn
Isoniazid	The therapeutic efficacy of Isoniazid can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Isoprenaline	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Isoprenaline.	Approved, Investigational
Isoxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Isoxicam.	Withdrawn
Isradipine	The serum concentration of Hydrocortisone can be increased when it is combined with Isradipine.	Approved, Investigational
Itopride	The therapeutic efficacy of Itopride can be decreased when used in combination with Hydrocortisone.	Investigational
Itraconazole	The metabolism of Hydrocortisone can be decreased when combined with Itraconazole.	Approved, Investigational
Ivermectin	The serum concentration of Hydrocortisone can be increased when it is combined with Ivermectin.	Approved, Investigational, Vet Approved
Ivosidenib	The serum concentration of Hydrocortisone can be increased when it is combined with Ivosidenib.	Approved, Investigational
Ixabepilone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ixabepilone.	Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.	Approved
Kebuzone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Kebuzone.	Experimental
Ketoconazole	The metabolism of Hydrocortisone can be decreased when combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ketorolac.	Approved
KRP-104	The therapeutic efficacy of KRP-104 can be decreased when used in combination with Hydrocortisone.	Investigational
L-Phenylalanine	The risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Hydrocortisone.	Approved, Investigational, Nutraceutical
Laniquidar	The serum concentration of Hydrocortisone can be increased when it is combined with Laniquidar.	Investigational
Lansoprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Hydrocortisone can be increased when it is combined with Lapatinib.	Approved, Investigational
Ledipasvir	The serum concentration of Hydrocortisone can be increased when it is combined with Ledipasvir.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Hydrocortisone.	Approved, Investigational
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hydrocortisone.	Approved
Letermovir	The serum concentration of Hydrocortisone can be increased when it is combined with Letermovir.	Approved, Investigational
Levofloxacin	The serum concentration of Hydrocortisone can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levonorgestrel	The serum concentration of Hydrocortisone can be increased when it is combined with Levonorgestrel.	Approved, Investigational
Levosalbutamol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Levosalbutamol.	Approved, Investigational
Lidocaine	The serum concentration of Hydrocortisone can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Hydrocortisone can be increased when it is combined with Linagliptin.	Approved
Linezolid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Linezolid.	Approved, Investigational
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone.	Approved
Lisuride	The metabolism of Lisuride can be decreased when combined with Hydrocortisone.	Approved, Investigational
Lixisenatide	The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Hydrocortisone.	Approved
Lobeglitazone	The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Lomefloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Lomefloxacin.	Approved, Investigational
Lomerizine	The serum concentration of Hydrocortisone can be increased when it is combined with Lomerizine.	Experimental
Lomitapide	The serum concentration of Hydrocortisone can be increased when it is combined with Lomitapide.	Approved, Investigational
Lomustine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Lomustine.	Approved, Investigational
Lonafarnib	The serum concentration of Hydrocortisone can be increased when it is combined with Lonafarnib.	Investigational
Lonazolac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lonazolac.	Experimental
Loperamide	The serum concentration of Hydrocortisone can be increased when it is combined with Loperamide.	Approved
Lopinavir	The metabolism of Hydrocortisone can be decreased when combined with Lopinavir.	Approved
Loratadine	The serum concentration of Hydrocortisone can be increased when it is combined with Loratadine.	Approved, Investigational
Lornoxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lornoxicam.	Approved, Investigational
Lorpiprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The serum concentration of Hydrocortisone can be increased when it is combined with Losartan.	Approved
Loteprednol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Loteprednol.	Approved
Lovastatin	The serum concentration of Hydrocortisone can be increased when it is combined with Lovastatin.	Approved, Investigational
Loxapine	The serum concentration of Hydrocortisone can be increased when it is combined with Loxapine.	Approved
Loxoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Loxoprofen.	Approved, Investigational
Luliconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lumiracoxib.	Approved, Investigational
Lynestrenol	The serum concentration of Hydrocortisone can be increased when it is combined with Lynestrenol.	Approved, Investigational
Lysergic Acid Diethylamide	The metabolism of Lysergic Acid Diethylamide can be decreased when combined with Hydrocortisone.	Illicit, Investigational, Withdrawn
Magaldrate	The bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.	Approved, Withdrawn
Magnesium carbonate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium carbonate.	Approved, Investigational
Magnesium hydroxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.	Approved
Magnesium peroxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium peroxide.	Experimental
Magnesium salicylate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Magnesium salicylate.	Approved
Magnesium silicate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium silicate.	Approved
Magnesium Trisilicate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The therapeutic efficacy of Malathion can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Maxacalcitol	The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Mecasermin	The therapeutic efficacy of Mecasermin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Mechlorethamine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mechlorethamine.	Approved, Investigational
Meclofenamic acid	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meclofenamic acid.	Approved, Vet Approved
Medroxyprogesterone acetate	The serum concentration of Hydrocortisone can be increased when it is combined with Medroxyprogesterone acetate.	Approved, Investigational
Medrysone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Mefenamic acid.	Approved
Mefloquine	The serum concentration of Hydrocortisone can be increased when it is combined with Mefloquine.	Approved, Investigational
Megestrol acetate	The serum concentration of Hydrocortisone can be increased when it is combined with Megestrol acetate.	Approved, Investigational, Vet Approved
Melengestrol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meloxicam.	Approved, Vet Approved
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Hydrocortisone.	Approved
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Hydrocortisone.	Approved, Investigational
Meprednisone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Meprednisone.	Approved, Investigational
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hydrocortisone.	Approved
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.	Approved
Mesterolone	The risk or severity of edema formation can be increased when Mesterolone is combined with Hydrocortisone.	Experimental
Metahexamide	The therapeutic efficacy of Metahexamide can be decreased when used in combination with Hydrocortisone.	Experimental
Metamizole	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Metamizole.	Approved, Investigational, Withdrawn
Metenolone	The risk or severity of edema formation can be increased when Metenolone is combined with Hydrocortisone.	Experimental
Metergoline	The metabolism of Metergoline can be decreased when combined with Hydrocortisone.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.	Approved
Methadone	The serum concentration of Hydrocortisone can be increased when it is combined with Methadone.	Approved
Methanesulfonyl Fluoride	The therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Hydrocortisone.	Investigational
Methimazole	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methimazole.	Approved
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Hydrocortisone.	Approved
Methyclothiazide	Hydrocortisone may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyl salicylate	The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.	Approved, Vet Approved
Methylergometrine	The metabolism of Methylergometrine can be decreased when combined with Hydrocortisone.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methylprednisolone.	Approved, Vet Approved
Methyltestosterone	The risk or severity of edema formation can be increased when Methyltestosterone is combined with Hydrocortisone.	Approved
Methysergide	The metabolism of Methysergide can be decreased when combined with Hydrocortisone.	Approved
Metoclopramide	The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Metocurine	The risk or severity of myopathy and weakness can be increased when Metocurine is combined with Hydrocortisone.	Approved
Metocurine Iodide	The risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Hydrocortisone.	Approved, Withdrawn
Metolazone	Hydrocortisone may increase the hypokalemic activities of Metolazone.	Approved
Metronidazole	The serum concentration of Hydrocortisone can be increased when it is combined with Metronidazole.	Approved
Mibefradil	The metabolism of Hydrocortisone can be decreased when combined with Mibefradil.	Investigational, Withdrawn
Mibolerone	The risk or severity of edema formation can be increased when Mibolerone is combined with Hydrocortisone.	Vet Approved
Miconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Hydrocortisone can be increased when it is combined with Midazolam.	Approved, Illicit
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Hydrocortisone.	Approved, Experimental
Mifepristone	The serum concentration of Hydrocortisone can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.	Approved
Minaprine	The therapeutic efficacy of Minaprine can be decreased when used in combination with Hydrocortisone.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Hydrocortisone.	Approved
Mitotane	The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mitoxantrone.	Approved, Investigational
Mivacurium	The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mizoribine.	Investigational
Modafinil	The serum concentration of Hydrocortisone can be decreased when it is combined with Modafinil.	Approved, Investigational
Mofebutazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Mofebutazone.	Experimental
Mometasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mometasone.	Approved, Vet Approved
Mometasone furoate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mometasone furoate.	Approved, Vet Approved
Monensin	The serum concentration of Hydrocortisone can be increased when it is combined with Monensin.	Vet Approved
Morniflumate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Morniflumate.	Approved
Moxifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Moxifloxacin.	Approved, Investigational
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.	Approved
Nabumetone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nabumetone.	Approved
Nafcillin	The serum concentration of Hydrocortisone can be decreased when it is combined with Nafcillin.	Approved, Investigational
Nalidixic Acid	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Nalidixic Acid.	Approved, Investigational
Naloxone	The metabolism of Hydrocortisone can be decreased when combined with Naloxone.	Approved, Vet Approved
Nandrolone	The risk or severity of edema formation can be increased when Nandrolone is combined with Hydrocortisone.	Experimental, Investigational
Nandrolone decanoate	The risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Hydrocortisone.	Approved, Illicit
Nandrolone phenpropionate	The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Hydrocortisone.	Approved, Illicit, Investigational
Naproxen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Naproxen.	Approved, Vet Approved
Natalizumab	The risk or severity of adverse effects can be increased when Natalizumab is combined with Hydrocortisone.	Approved, Investigational
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
NBI-6024	The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Hydrocortisone.	Investigational
Nefazodone	The metabolism of Hydrocortisone can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelarabine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nelarabine.	Approved, Investigational
Nelfinavir	The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.	Approved
Nemonoxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Nemonoxacin.	Investigational
Neosaxitoxin	The risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Hydrocortisone.	Investigational
Neostigmine	The therapeutic efficacy of Neostigmine can be decreased when used in combination with Hydrocortisone.	Approved, Vet Approved
Nepafenac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nepafenac.	Approved, Investigational
Neratinib	The serum concentration of Hydrocortisone can be increased when it is combined with Neratinib.	Approved, Investigational
Netoglitazone	The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Hydrocortisone.	Experimental
Netupitant	The serum concentration of Hydrocortisone can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Hydrocortisone can be increased when it is combined with Nicardipine.	Approved, Investigational
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Hydrocortisone.	Approved, Investigational
Nicorandil	The risk or severity of ulceration can be increased when Hydrocortisone is combined with Nicorandil.	Approved, Investigational
Nifenazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nifenazone.	Experimental
Niflumic Acid	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Niflumic Acid.	Approved
Nigericin	The serum concentration of Hydrocortisone can be increased when it is combined with Nigericin.	Experimental
Niguldipine	The serum concentration of Hydrocortisone can be increased when it is combined with Niguldipine.	Experimental
Nilotinib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nilotinib.	Approved, Investigational
Nimesulide	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nimesulide.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Hydrocortisone.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be decreased when it is combined with Hydrocortisone.	Approved
Nisoldipine	The serum concentration of Hydrocortisone can be increased when it is combined with Nisoldipine.	Approved
Nitrendipine	The serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine.	Approved, Investigational
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone.	Investigational
NN344	The therapeutic efficacy of NN344 can be decreased when used in combination with Hydrocortisone.	Investigational
Nomegestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Nomegestrol.	Approved
Norelgestromin	The serum concentration of Hydrocortisone can be increased when it is combined with Norelgestromin.	Approved, Investigational
Norepinephrine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Norepinephrine.	Approved
Norethisterone	The serum concentration of Hydrocortisone can be increased when it is combined with Norethisterone.	Approved
Norfloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Norfloxacin.	Approved
Norgestimate	The serum concentration of Hydrocortisone can be increased when it is combined with Norgestimate.	Approved, Investigational
Norgestrel	The serum concentration of Hydrocortisone can be increased when it is combined with Norgestrel.	Approved
Norgestrienone	The serum concentration of Hydrocortisone can be increased when it is combined with Norgestrienone.	Experimental
NS-398	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with NS-398.	Experimental
Obinutuzumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Obinutuzumab.	Approved, Investigational
Ocrelizumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ocrelizumab.	Approved, Investigational
Ofloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ofloxacin.	Approved
Olaparib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Olaparib.	Approved
Olodaterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Olodaterol.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.	Approved
Omarigliptin	The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Omeprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
ONT-093	The serum concentration of Hydrocortisone can be increased when it is combined with ONT-093.	Investigational
Orbifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Orbifloxacin.	Vet Approved
Orciprenaline	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Orciprenaline.	Approved
Osimertinib	The serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib.	Approved
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone.	Approved, Investigational
Oxandrolone	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Oxaprozin.	Approved
Oxolinic acid	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Oxolinic acid.	Experimental
Oxymetholone	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Oxyphenbutazone.	Approved, Withdrawn
Paclitaxel	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The serum concentration of Hydrocortisone can be increased when it is combined with Paliperidone.	Approved
Pancuronium	The risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Hydrocortisone.	Approved
Panobinostat	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Pantoprazole.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paramethasone.	Approved
Paraoxon	The therapeutic efficacy of Paraoxon can be decreased when used in combination with Hydrocortisone.	Experimental
Parecoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Parecoxib.	Approved
Paricalcitol	The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Paritaprevir	The serum concentration of Hydrocortisone can be increased when it is combined with Paritaprevir.	Approved, Investigational
Paroxetine	The serum concentration of Hydrocortisone can be increased when it is combined with Paroxetine.	Approved, Investigational
Pazopanib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazopanib.	Approved
Pazufloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pefloxacin.	Approved
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone.	Approved, Investigational
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Peginterferon alfa-2a.	Approved, Investigational
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Peginterferon alfa-2b.	Approved
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hydrocortisone.	Approved, Investigational
Pentamidine	The therapeutic efficacy of Pentamidine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pentazocine	The serum concentration of Hydrocortisone can be increased when it is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Hydrocortisone.	Approved, Investigational
Pergolide	The metabolism of Pergolide can be decreased when combined with Hydrocortisone.	Approved, Investigational, Vet Approved, Withdrawn
Pethidine	The serum concentration of Hydrocortisone can be increased when it is combined with Pethidine.	Approved
PF-00610355	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with PF-00610355.	Investigational
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Withdrawn
Phenobarbital	The serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenyl aminosalicylate	The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone.	Approved
Phenylbutazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Phenylbutazone.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Phenylpropanolamine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Phenytoin	The serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pibrentasvir	The serum concentration of Hydrocortisone can be increased when it is combined with Pibrentasvir.	Approved, Investigational
Pimecrolimus	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pimecrolimus.	Approved, Investigational
Pimozide	The serum concentration of Hydrocortisone can be increased when it is combined with Pimozide.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pipecuronium	The risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Hydrocortisone.	Approved
Pipemidic acid	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Pipemidic acid.	Experimental
Pirarubicin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pirarubicin.	Investigational
Pirbuterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Pirbuterol.	Approved
Piretanide	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Piretanide.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pirfenidone.	Approved, Investigational
Piromidic acid	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Piromidic acid.	Experimental
Piroxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Piroxicam.	Approved, Investigational
Pirprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Pirprofen.	Experimental
Pitolisant	The serum concentration of Hydrocortisone can be decreased when it is combined with Pitolisant.	Approved, Investigational
Polythiazide	Hydrocortisone may increase the hypokalemic activities of Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Pomalidomide is combined with Hydrocortisone.	Approved
Ponatinib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ponatinib.	Approved, Investigational
Posaconazole	The metabolism of Hydrocortisone can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pralatrexate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pralatrexate.	Approved, Investigational
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pranoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Pranoprofen.	Experimental, Investigational
Prasterone	The risk or severity of edema formation can be increased when Prasterone is combined with Hydrocortisone.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of edema formation can be increased when Prasterone sulfate is combined with Hydrocortisone.	Investigational
Prazosin	The serum concentration of Hydrocortisone can be increased when it is combined with Prazosin.	Approved
Prednicarbate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednicarbate.	Approved, Investigational
Prednisolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Hydrocortisone.	Approved, Vet Approved
Prednylidene	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednylidene.	Experimental
Primaquine	The serum concentration of Hydrocortisone can be increased when it is combined with Primaquine.	Approved
Primidone	The serum concentration of Hydrocortisone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Procarbazine.	Approved, Investigational
Procaterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Procaterol.	Approved, Investigational
Progesterone	The serum concentration of Hydrocortisone can be increased when it is combined with Progesterone.	Approved, Vet Approved
Proglumetacin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Proglumetacin.	Experimental
Promethazine	The serum concentration of Hydrocortisone can be increased when it is combined with Promethazine.	Approved, Investigational
Propacetamol	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Propacetamol.	Approved, Investigational
Propafenone	The serum concentration of Hydrocortisone can be increased when it is combined with Propafenone.	Approved
Propofol	The serum concentration of Hydrocortisone can be increased when it is combined with Propofol.	Approved, Investigational, Vet Approved
Propylthiouracil	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Propylthiouracil.	Approved, Investigational
Propyphenazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Propyphenazone.	Experimental
Proquazone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Proquazone.	Experimental
Protokylol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Protokylol.	Approved, Vet Approved
Protriptyline	The serum concentration of Hydrocortisone can be increased when it is combined with Protriptyline.	Approved
Prulifloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Prulifloxacin.	Investigational
Pyrantel	The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Hydrocortisone.	Approved, Vet Approved
Pyridostigmine	The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Quercetin	The serum concentration of Hydrocortisone can be increased when it is combined with Quercetin.	Experimental, Investigational
Quinacrine	The serum concentration of Hydrocortisone can be increased when it is combined with Quinacrine.	Approved, Investigational
Quinethazone	Hydrocortisone may increase the hypokalemic activities of Quinethazone.	Approved
Quingestanol	The serum concentration of Hydrocortisone can be increased when it is combined with Quingestanol.	Experimental
Quinidine	The serum concentration of Hydrocortisone can be increased when it is combined with Quinidine.	Approved, Investigational
Quinine	The serum concentration of Hydrocortisone can be decreased when it is combined with Quinine.	Approved
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Racepinephrine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Racepinephrine.	Approved
Raltitrexed	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Raltitrexed.	Approved, Investigational
Ranitidine	The serum concentration of Hydrocortisone can be increased when it is combined with Ranitidine.	Approved
Rapacuronium	The risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Hydrocortisone.	Withdrawn
Reboxetine	The serum concentration of Hydrocortisone can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Hydrocortisone can be increased when it is combined with Regorafenib.	Approved
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Reserpine	The serum concentration of Hydrocortisone can be increased when it is combined with Reserpine.	Approved, Investigational
Reversin 121	The serum concentration of Hydrocortisone can be increased when it is combined with Reversin 121.	Experimental
Rifampicin	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin.	Approved
Rifamycin	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifamycin.	Investigational
Rifapentine	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifaximin.	Approved, Investigational
Rilonacept	The risk or severity of adverse effects can be increased when Rilonacept is combined with Hydrocortisone.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.	Approved
Rimexolone	The serum concentration of Hydrocortisone can be decreased when it is combined with Rimexolone.	Approved
Rindopepimut	The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Hydrocortisone.	Investigational
Risperidone	The metabolism of Hydrocortisone can be decreased when combined with Risperidone.	Approved, Investigational
Ritodrine	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Ritodrine.	Approved, Investigational
Ritonavir	The metabolism of Hydrocortisone can be decreased when combined with Ritonavir.	Approved, Investigational
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone.	Approved
Rivastigmine	The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Rivoglitazone	The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Robenacoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Robenacoxib.	Experimental, Vet Approved
Rocuronium	The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Hydrocortisone.	Approved
Rofecoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Rofecoxib.	Approved, Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Hydrocortisone.	Approved
Rolapitant	The serum concentration of Hydrocortisone can be increased when it is combined with Rolapitant.	Approved, Investigational
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Rosoxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Rosoxacin.	Approved, Investigational
Rotavirus Vaccine	The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Hydrocortisone.	Approved
Rubella virus vaccine	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Rucaparib	The serum concentration of Hydrocortisone can be increased when it is combined with Rucaparib.	Approved, Investigational
Rufloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Rufloxacin.	Experimental
Ruxolitinib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ruxolitinib.	Approved
Salbutamol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salbutamol.	Approved, Vet Approved
Salicylamide	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.	Approved, Investigational, Vet Approved
Salinomycin	The serum concentration of Hydrocortisone can be increased when it is combined with Salinomycin.	Vet Approved
Salmeterol	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salmeterol.	Approved
Salmonella typhi ty2 vi polysaccharide antigen	The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Hydrocortisone.	Approved
Salmonella typhi Ty21a live antigen	The risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Hydrocortisone.	Approved
Salmonella typhi Ty21a live antigen	The therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Hydrocortisone.	Approved
Salsalate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salsalate.	Approved
Saquinavir	The metabolism of Hydrocortisone can be decreased when combined with Saquinavir.	Approved, Investigational
Sarafloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sarafloxacin.	Vet Approved, Withdrawn
Sarilumab	The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.	Approved
SC-236	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with SC-236.	Experimental, Investigational
Secukinumab	The risk or severity of adverse effects can be increased when Secukinumab is combined with Hydrocortisone.	Approved
Semaglutide	The therapeutic efficacy of Semaglutide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Seocalcitol	The therapeutic efficacy of Seocalcitol can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Sertraline	The serum concentration of Hydrocortisone can be increased when it is combined with Sertraline.	Approved
Siltuximab	The serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Hydrocortisone.	Approved, Investigational
Sitafloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sitafloxacin.	Experimental, Investigational
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Sodium bicarbonate	The bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.	Approved
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Hydrocortisone.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrocortisone.	Investigational
Sparfloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sparfloxacin.	Approved, Investigational
SRP 299	The therapeutic efficacy of SRP 299 can be decreased when used in combination with Hydrocortisone.	Investigational
St. John's Wort	The serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stanolone	The risk or severity of edema formation can be increased when Stanolone is combined with Hydrocortisone.	Illicit, Investigational
Stanozolol	The risk or severity of fluid retention can be increased when Hydrocortisone is combined with Stanozolol.	Approved, Vet Approved
Staurosporine	The serum concentration of Hydrocortisone can be increased when it is combined with Staurosporine.	Experimental
Stepronin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Stepronin.	Approved
Stiripentol	The serum concentration of Hydrocortisone can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Hydrocortisone.	Approved, Investigational
Succinylcholine	The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone.	Approved
Sulfadiazine	The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Hydrocortisone.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sulfasalazine.	Approved
Sulfisoxazole	The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Hydrocortisone.	Approved, Vet Approved
Sulindac	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Sulindac.	Approved, Investigational
Sunitinib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sunitinib.	Approved, Investigational
Suprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Suprofen.	Approved, Withdrawn
Suvorexant	The serum concentration of Hydrocortisone can be increased when it is combined with Suvorexant.	Approved, Investigational
Suxibuzone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Suxibuzone.	Experimental
Tacalcitol	The therapeutic efficacy of Tacalcitol can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Tacrine	The therapeutic efficacy of Tacrine can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone.	Approved, Investigational
Talniflumate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Talniflumate.	Approved
Tamoxifen	The serum concentration of Hydrocortisone can be increased when it is combined with Tamoxifen.	Approved
Tariquidar	The serum concentration of Hydrocortisone can be increased when it is combined with Tariquidar.	Investigational
Taspoglutide	The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Hydrocortisone.	Investigational
Tecemotide	The therapeutic efficacy of Tecemotide can be decreased when used in combination with Hydrocortisone.	Investigational
Technetium Tc-99m ciprofloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Technetium Tc-99m ciprofloxacin.	Investigational
Tedizolid phosphate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tedizolid phosphate.	Approved
Telaprevir	The metabolism of Hydrocortisone can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Hydrocortisone can be decreased when combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Hydrocortisone can be increased when it is combined with Telmisartan.	Approved, Investigational
Temafloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Temafloxacin.	Withdrawn
Temozolomide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temozolomide.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temsirolimus.	Approved
Teneligliptin	The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Hydrocortisone.	Investigational
Tenidap	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tenidap.	Experimental
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Hydrocortisone.	Approved
Tenoxicam	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tenoxicam.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tepoxalin.	Vet Approved
Terbutaline	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Terbutaline.	Approved
Terfenadine	The serum concentration of Hydrocortisone can be increased when it is combined with Terfenadine.	Approved, Withdrawn
Terguride	The metabolism of Terguride can be decreased when combined with Hydrocortisone.	Experimental
Teriflunomide	The serum concentration of Hydrocortisone can be increased when it is combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Hydrocortisone can be increased when it is combined with Tesmilifene.	Investigational
Testosterone	The risk or severity of edema formation can be increased when Testosterone is combined with Hydrocortisone.	Approved, Investigational
Testosterone cypionate	The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Hydrocortisone.	Approved
Testosterone enantate benzilic acid hydrazone	The risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Hydrocortisone.	Approved, Experimental
Testosterone enanthate	The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Hydrocortisone.	Approved
Testosterone propionate	The risk or severity of edema formation can be increased when Testosterone propionate is combined with Hydrocortisone.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone succinate	The risk or severity of edema formation can be increased when Testosterone succinate is combined with Hydrocortisone.	Experimental
Testosterone undecanoate	The risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Hydrocortisone.	Approved, Investigational
Tetracycline	The excretion of Hydrocortisone can be decreased when combined with Tetracycline.	Approved, Vet Approved
Tetrandrine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tetrandrine.	Experimental
TG4010	The therapeutic efficacy of TG4010 can be decreased when used in combination with Hydrocortisone.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Hydrocortisone.	Approved, Investigational
Tiaprofenic acid	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tiaprofenic acid.	Approved
Ticagrelor	The serum concentration of Hydrocortisone can be increased when it is combined with Ticagrelor.	Approved
Tinoridine	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tinoridine.	Investigational
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Hydrocortisone.	Approved
Tipifarnib	The serum concentration of Hydrocortisone can be increased when it is combined with Tipifarnib.	Investigational
Tipranavir	The metabolism of Hydrocortisone can be decreased when combined with Tipranavir.	Approved, Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tixocortol.	Approved, Withdrawn
Tocilizumab	The serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The risk or severity of adverse effects can be increased when Tofacitinib is combined with Hydrocortisone.	Approved, Investigational
Tofacitinib	Hydrocortisone may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Tolfenamic Acid	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tolmetin.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Hydrocortisone.	Approved
Topotecan	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Topotecan.	Approved, Investigational
Torasemide	The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Torasemide.	Approved
Toremifene	The serum concentration of Hydrocortisone can be increased when it is combined with Toremifene.	Approved, Investigational
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone.	Approved, Investigational
Trabectedin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trabectedin.	Approved, Investigational
Trastuzumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trastuzumab.	Approved, Investigational
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trastuzumab emtansine.	Approved, Investigational
Trestolone	The risk or severity of edema formation can be increased when Trestolone is combined with Hydrocortisone.	Investigational
Trestolone acetate	The risk or severity of edema formation can be increased when Trestolone acetate is combined with Hydrocortisone.	Experimental
Tretinoin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Hydrocortisone.	Approved, Vet Approved
Trichlorfon	The therapeutic efficacy of Trichlorfon can be decreased when used in combination with Hydrocortisone.	Vet Approved
Trichlormethiazide	Hydrocortisone may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Hydrocortisone can be increased when it is combined with Trifluoperazine.	Approved, Investigational
Triflupromazine	The serum concentration of Hydrocortisone can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trifluridine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trifluridine.	Approved, Investigational
Trilostane	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trilostane.	Approved, Investigational, Vet Approved, Withdrawn
Trimethoprim	The serum concentration of Hydrocortisone can be increased when it is combined with Trimethoprim.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Triptolide.	Investigational
Trofosfamide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trofosfamide.	Investigational
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Trolamine salicylate	The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.	Approved
Troleandomycin	The metabolism of Hydrocortisone can be decreased when combined with Troleandomycin.	Approved
Trovafloxacin	The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tubocurarine	The risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Hydrocortisone.	Approved
Typhoid Vaccine	The therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Hydrocortisone.	Approved
Tyrothricin	The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Hydrocortisone.	Approved
Ulipristal	The serum concentration of Hydrocortisone can be increased when it is combined with Ulipristal.	Approved
Ulobetasol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ulobetasol.	Approved
Ustekinumab	The risk or severity of adverse effects can be increased when Ustekinumab is combined with Hydrocortisone.	Approved, Investigational
Valdecoxib	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Valdecoxib.	Approved, Investigational, Withdrawn
Valinomycin	The serum concentration of Hydrocortisone can be increased when it is combined with Valinomycin.	Experimental
Valspodar	The serum concentration of Hydrocortisone can be increased when it is combined with Valspodar.	Investigational
Varicella Zoster Vaccine (Live/Attenuated)	The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Hydrocortisone.	Approved
Varicella Zoster Vaccine (Live/Attenuated)	The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Hydrocortisone.	Approved
Vecuronium	The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Hydrocortisone.	Approved
Vedolizumab	The risk or severity of adverse effects can be increased when Vedolizumab is combined with Hydrocortisone.	Approved
Velpatasvir	The serum concentration of Hydrocortisone can be increased when it is combined with Velpatasvir.	Approved, Investigational
Vemurafenib	The serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	The serum concentration of Hydrocortisone can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Hydrocortisone can be increased when it is combined with Verapamil.	Approved
Vibrio cholerae CVD 103-HgR strain live antigen	The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Hydrocortisone.	Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Vilanterol	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Vilanterol.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Hydrocortisone.	Approved
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Hydrocortisone.	Approved, Investigational
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Hydrocortisone.	Approved, Investigational
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Hydrocortisone.	Approved, Investigational
Vitamin D	The therapeutic efficacy of Vitamin D can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical, Vet Approved
Voacamine	The serum concentration of Hydrocortisone can be increased when it is combined with Voacamine.	Approved, Investigational
Voclosporin	The risk or severity of adverse effects can be increased when Voclosporin is combined with Hydrocortisone.	Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Vorapaxar	The serum concentration of Hydrocortisone can be increased when it is combined with Vorapaxar.	Approved
Voriconazole	The metabolism of Hydrocortisone can be decreased when combined with Voriconazole.	Approved, Investigational
Vorinostat	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Vorinostat.	Approved, Investigational
Voxilaprevir	The serum concentration of Hydrocortisone can be increased when it is combined with Voxilaprevir.	Approved, Investigational
Warfarin	The therapeutic efficacy of Warfarin can be increased when used in combination with Hydrocortisone.	Approved
Wortmannin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Wortmannin.	Experimental
Yellow Fever Vaccine	The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Hydrocortisone.	Approved, Investigational
Yellow Fever Vaccine	The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Yohimbine	The serum concentration of Hydrocortisone can be increased when it is combined with Yohimbine.	Approved, Investigational, Vet Approved
Zaltoprofen	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Zaltoprofen.	Approved, Investigational
Zidovudine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Zidovudine.	Approved
Ziprasidone	The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.	Approved
Zomepirac	The serum concentration of Hydrocortisone can be increased when it is combined with Zomepirac.	Withdrawn
Zosuquidar	The serum concentration of Hydrocortisone can be increased when it is combined with Zosuquidar.	Investigational

Food Interactions

• Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

References

Synthesis Reference

Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, "Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof." U.S. Patent US4264584, issued March, 1974.

US4264584

General References

1. de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. [PubMed:12932892]
2. Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. [PubMed:6461917]
3. KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. [PubMed:13233328]

External Links

Human Metabolome Database

HMDB0000063

KEGG Drug

D00088

KEGG Compound

C00735

PubChem Compound

5754

PubChem Substance

46505089

ChemSpider

5551

BindingDB

13775

ChEBI

17650

ChEMBL

CHEMBL389621

Therapeutic Targets Database

DAP000718

PharmGKB

PA449905

IUPHAR

2868

Guide to Pharmacology

GtP Drug Page

HET

HCY

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Hydrocortisone

ATC Codes

S03CA04 — Hydrocortisone and antiinfectives

• S03CA — Corticosteroids and antiinfectives in combination
• S03C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
• S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
• S — SENSORY ORGANS

S01CB03 — Hydrocortisone

• S01CB — Corticosteroids/antiinfectives/mydriatics in combination
• S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S01CA03 — Hydrocortisone and antiinfectives

• S01CA — Corticosteroids and antiinfectives in combination
• S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S02BA01 — Hydrocortisone

• S02BA — Corticosteroids
• S02B — CORTICOSTEROIDS
• S02 — OTOLOGICALS
• S — SENSORY ORGANS

S02CA03 — Hydrocortisone and antiinfectives

• S02CA — Corticosteroids and antiinfectives in combination
• S02C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
• S02 — OTOLOGICALS
• S — SENSORY ORGANS

D07AA02 — Hydrocortisone

• D07AA — Corticosteroids, weak (group I)
• D07A — CORTICOSTEROIDS, PLAIN
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

C05AA01 — Hydrocortisone

• C05AA — Corticosteroids
• C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
• C05 — VASOPROTECTIVES
• C — CARDIOVASCULAR SYSTEM

D07BA04 — Hydrocortisone and antiseptics

• D07BA — Corticosteroids, weak, combinations with antiseptics
• D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

A01AC03 — Hydrocortisone

• A01AC — Corticosteroids for local oral treatment
• A01A — STOMATOLOGICAL PREPARATIONS
• A01 — STOMATOLOGICAL PREPARATIONS
• A — ALIMENTARY TRACT AND METABOLISM

D07CA01 — Hydrocortisone and antibiotics

• D07CA — Corticosteroids, weak, combinations with antibiotics
• D07C — CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

S01BA02 — Hydrocortisone

• S01BA — Corticosteroids, plain
• S01B — ANTIINFLAMMATORY AGENTS
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S01BB01 — Hydrocortisone and mydriatics

• S01BB — Corticosteroids and mydriatics in combination
• S01B — ANTIINFLAMMATORY AGENTS
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

A07EA02 — Hydrocortisone

• A07EA — Corticosteroids acting locally
• A07E — INTESTINAL ANTIINFLAMMATORY AGENTS
• A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
• A — ALIMENTARY TRACT AND METABOLISM

R01AD60 — Hydrocortisone, combinations

• R01AD — Corticosteroids
• R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
• R01 — NASAL PREPARATIONS
• R — RESPIRATORY SYSTEM

H02AB09 — Hydrocortisone

• H02AB — Glucocorticoids
• H02A — CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
• H02 — CORTICOSTEROIDS FOR SYSTEMIC USE
• H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

D07XA01 — Hydrocortisone

• D07XA — Corticosteroids, weak, other combinations
• D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

AHFS Codes

• 68:04.00 — Adrenals
• 84:06.00 — Anti-inflammatory Agents
• 56:36.00 — Anti-inflammatory Agents

PDB Entries

2v95 / 2vdy / 4c49 / 4p6x / 5hgc

FDA label

Download (30 KB)

MSDS

Download (73.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Other	Insulin Resistance	1
0	Completed	Treatment	Fibromyalgia	1
0	Recruiting	Basic Science	Depression	1
0	Recruiting	Basic Science	Healthy Volunteers	1
0	Recruiting	Basic Science	Human Immunodeficiency Virus (HIV)	1
0	Withdrawn	Basic Science	BMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome	2
1	Active Not Recruiting	Basic Science	BMI >30 kg/m2	1
1	Active Not Recruiting	Treatment	Rotator Cuff Tear - Partial Thickness	1
1	Completed	Not Available	Infection NOS	1
1	Completed	Not Available	Relative Adrenal Insufficiency / Sepsis	1
1	Completed	Basic Science	Healthy Volunteers	2
1	Completed	Basic Science	Healthy Volunteers / Inflammatory Reaction / Pain	1
1	Completed	Other	Adrenal Insufficiency	1
1	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)	1
1	Completed	Treatment	Adrenal Insufficiency	2
1	Completed	Treatment	Adrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH)	1
1	Completed	Treatment	Arterial Hypotension / Blood Pressures / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants	1
1	Completed	Treatment	Erythemas / Pain	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
1	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Completed	Treatment	Psoriasis Vulgaris (Plaque Psoriasis)	1
1	Recruiting	Basic Science	Sleep Restriction	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse	1
1	Recruiting	Treatment	Heroin Dependence / Opioid Use Disorders	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Lymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)	1
1	Unknown Status	Treatment	Ovarian Epithelial Cancer	1
1	Withdrawn	Basic Science	Diabetes, Diabetes Mellitus Type 1	1
1, 2	Active Not Recruiting	Treatment	Inhospital Cardiac Arrest	1
1, 2	Completed	Diagnostic	Systemic Lupus Erythematosus (SLE)	1
1, 2	Completed	Treatment	21-Hydroxylase Deficiency / Adrenogenital Syndrome / Congenital Adrenal Hyperplasia (CAH)	1
1, 2	Completed	Treatment	Cardiac Arrest	1
1, 2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Recruiting	Treatment	Addison's Disease / Adrenal Hyperplasia Congenital	1
1, 2	Recruiting	Treatment	Adult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma	1
1, 2	Terminated	Basic Science	Renin Angiotensin	1
1, 2	Terminated	Treatment	Adenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
1, 2	Terminated	Treatment	Anaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma	1
1, 2	Terminated	Treatment	Prostate Cancer	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	2
2	Active Not Recruiting	Treatment	Lymphoma, Lymphoblastic	1
2	Active Not Recruiting	Treatment	Prostate Cancer	1
2	Completed	Not Available	Postoperative Complications / Postoperative Pancreatitis	1
2	Completed	Prevention	Chronic Lung Disease of Prematurity	1
2	Completed	Prevention	Chronic Lung Disease of Prematurity / Encephalomalacia / Premature Births	1
2	Completed	Prevention	Memory Disturbances	1
2	Completed	Supportive Care	Advanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant	1
2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL)	1
2	Completed	Treatment	Acute Respiratory Distress Syndrome (ARDS) / Multiple Organ Failure	1
2	Completed	Treatment	Adenocarcinoma, Prostate / Prostate Cancer	1
2	Completed	Treatment	Adrenal Hyperplasia, Congenital	1
2	Completed	Treatment	Adrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH) / Excess Androgen	1
2	Completed	Treatment	Angioedema	1
2	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Blood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome	1
2	Completed	Treatment	Blood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous	1
2	Completed	Treatment	Cardiac Output, Low	1
2	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Hemorrhoids	1
2	Completed	Treatment	Jet Lag Syndrome	1
2	Completed	Treatment	Leukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Leukemias	1
2	Completed	Treatment	Lymphohistiocytosis, Hemophagocytic	1
2	Completed	Treatment	Opioid Dependence	1
2	Completed	Treatment	Paediatric Sepsis / Pediatric Sepsis / Sepsis	1
2	Completed	Treatment	Prostate Cancer	1
2	Completed	Treatment	Prurigo Nodularis	1
2	Completed	Treatment	Rash	1
2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Not Yet Recruiting	Basic Science	Adolescent Development / Borderline Personality Disorder (BPD)	1
2	Not Yet Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)	1
2	Not Yet Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	1
2	Recruiting	Treatment	Acute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)	1
2	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Adrenal Hyperplasia, Congenital	1
2	Recruiting	Treatment	Apomorphine-induced Skin Reactions / Parkinson's Disease (PD)	1
2	Recruiting	Treatment	Colorectal Cancers / Head and Neck Carcinoma	1
2	Recruiting	Treatment	Critically Ill / Sepsis / Shock, Septic / Vasoplegic Syndrome	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Prostate Cancer	1
2	Recruiting	Treatment	Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Severe Sepsis / Shock, Septic	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
2	Terminated	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia	1
2	Terminated	Treatment	Blood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)	1
2	Terminated	Treatment	Phobic Disorders	1
2	Unknown Status	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Unknown Status	Treatment	Addison's Disease	1
2	Unknown Status	Treatment	Cirrhosis With Ascites	1
2	Unknown Status	Treatment	Injuries, Whiplash	1
2	Unknown Status	Treatment	Leukemias	1
2, 3	Active Not Recruiting	Treatment	Asphyxia / Hypoxic-Ischaemic Encephalopathy	1
2, 3	Active Not Recruiting	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma	1
2, 3	Completed	Prevention	Injuries, Multiple	1
2, 3	Completed	Treatment	Addison's Disease	1
2, 3	Completed	Treatment	Adrenal Insufficiency	1
2, 3	Completed	Treatment	Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2, 3	Recruiting	Treatment	Left Ventricular Remodeling / ST Segment Elevation Myocardial Infarction (STEMI)	1
2, 3	Recruiting	Treatment	Osteoarthritis, Shoulder	1
2, 3	Unknown Status	Treatment	Mortality / Ventilations, Mechanical	1
3	Active Not Recruiting	Treatment	Cardiovascular Insufficiency / Infant, Newborn, Diseases	1
3	Completed	Supportive Care	Cardiac Toxicity / Leukemias / Malignant Lymphomas	1
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Completed	Treatment	Alcohol Craving / Stress, Physiological / Stress, Psychological	1
3	Completed	Treatment	Alopecia Areata (AA)	1
3	Completed	Treatment	Cardiac Arrest	1
3	Completed	Treatment	Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Completed	Treatment	Chronic Lung Disease of Prematurity	1
3	Completed	Treatment	Coagulation Dysfunction in Septic Shock / Hemodynamic Improvement Induced by Hydrocortisone	1
3	Completed	Treatment	Healthy Volunteers	1
3	Completed	Treatment	Herpes Labialis	1
3	Completed	Treatment	Leukemias / Malignant Lymphomas	1
3	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
3	Completed	Treatment	Neonatal Hypotension	1
3	Completed	Treatment	Oral Submucous Fibrosis	1
3	Completed	Treatment	Otitis Externa	1
3	Completed	Treatment	Patient Admitted in Reanimation	1
3	Completed	Treatment	Prostate Cancer	1
3	Completed	Treatment	Psoriasis Vulgaris (Plaque Psoriasis)	1
3	Completed	Treatment	Sepsis / Shock, Septic	1
3	Completed	Treatment	Severe Sepsis	1
3	Completed	Treatment	Shock, Septic	3
3	Not Yet Recruiting	Supportive Care	Sepsis	1
3	Not Yet Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	1
3	Not Yet Recruiting	Treatment	Immune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic	1
3	Recruiting	Prevention	Chronic Lung Disease of Prematurity / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Very Low Birth Weight Infant	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukemia, Pediatric	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
3	Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	2
3	Recruiting	Treatment	Liver Cirrhosis	1
3	Recruiting	Treatment	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	1
3	Suspended	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Terminated	Treatment	Evidence of Liver Transplantation / Transplantations	1
3	Terminated	Treatment	Influenza in Humans / Viral Pneumonia	1
3	Terminated	Treatment	Prostatic Neoplasms	1
3	Unknown Status	Treatment	Low Back Pain (LBP)	1
4	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
4	Completed	Not Available	Minor burns	1
4	Completed	Basic Science	Feeling Anxious	1
4	Completed	Basic Science	Healthy Volunteers	1
4	Completed	Basic Science	Stress Disorders, Posttraumatic	1
4	Completed	Prevention	Postoperative Inflammatory Response	1
4	Completed	Prevention	Posttraumatic Stress Disorders / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
4	Completed	Treatment	Adrenal Insufficiency	1
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	Atopic Dermatitis (AD)	1
4	Completed	Treatment	Atopic Dermatitis (AD) / Psoriasis	1
4	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Completed	Treatment	Coronary Artery Disease / Mitral Valve Regurgitation	1
4	Completed	Treatment	Hip Injuries	1
4	Completed	Treatment	Hyperglycemias	1
4	Completed	Treatment	Knee Replacement Surgery	1
4	Completed	Treatment	Rheumatic Diseases	1
4	Completed	Treatment	Shock	1
4	Completed	Treatment	Shock, Septic	1
4	Completed	Treatment	Snake Bites	1
4	Enrolling by Invitation	Treatment	Adrenal Insufficiency	1
4	Enrolling by Invitation	Treatment	Corticotropin Deficiency / Fasting	1
4	Enrolling by Invitation	Treatment	Granuloma / Tracheostomy care	1
4	Recruiting	Prevention	Neoplasms, Pancreatic / Pancreatic Fistula	1
4	Recruiting	Supportive Care	Rheumatoid Arthritis	1
4	Recruiting	Treatment	Atopic Dermatitis (AD)	1
4	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
4	Recruiting	Treatment	Critical Illness / Fluid Overload / Sepsis / Shock, Septic	1
4	Recruiting	Treatment	Function of Renal Transplant	1
4	Recruiting	Treatment	Granulomatous Mastitis	1
4	Recruiting	Treatment	Ulcerative Colitis (UC)	2
4	Terminated	Not Available	Asthma Bronchial	1
4	Terminated	Treatment	Partial Corticotrope Insufficiency	1
4	Terminated	Treatment	Shock, Septic	1
4	Unknown Status	Treatment	Acute Respiratory Distress Syndrome (ARDS) / Adrenal Insufficiency	1
4	Unknown Status	Treatment	Crohn's Disease (CD)	1
4	Unknown Status	Treatment	Pituitary Neoplasms / Postsurgical craniopharyngioma	1
4	Withdrawn	Treatment	Adrenal Insufficiency / Sepsis	1
4	Withdrawn	Treatment	Atopic Dermatitis (AD)	1
4	Withdrawn	Treatment	Phimosis	1
4	Withdrawn	Treatment	Post-Traumatic Stress Disorder (PTSD)	1
Not Available	Active Not Recruiting	Prevention	Dialysis Hypotension	1
Not Available	Active Not Recruiting	Supportive Care	Sjögren's Syndrome	1
Not Available	Completed	Not Available	Anxiety Disorders / Major Depressive Disorder (MDD)	1
Not Available	Completed	Not Available	Dependence, Cocaine	1
Not Available	Completed	Not Available	Heroin Dependence / Learning and Memory	1
Not Available	Completed	Not Available	Knee Osteoarthritis (Knee OA)	1
Not Available	Completed	Not Available	Sepsis	1
Not Available	Completed	Basic Science	Intrusive Memories	1
Not Available	Completed	Basic Science	Posttraumatic Stress Disorders	1
Not Available	Completed	Prevention	Fevers / Hemodynamics Instability / Hypothermia / Idiopathic orthostatic hypotension	1
Not Available	Completed	Screening	Other Diseases or Conditions	1
Not Available	Completed	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Severe Sepsis / Shock, Septic	1
Not Available	Completed	Treatment	Addison's Disease	1
Not Available	Completed	Treatment	Addison's Disease / BMI >30 kg/m2	1
Not Available	Completed	Treatment	Adrenal Hyperplasia, Congenital	1
Not Available	Completed	Treatment	Atopic Dermatitis (AD)	1
Not Available	Completed	Treatment	Heart Arrest	1
Not Available	Completed	Treatment	Heart Disease Congenital Complex	1
Not Available	Completed	Treatment	PTSD	1
Not Available	Completed	Treatment	Phobic Disorders	1
Not Available	Completed	Treatment	Pituitary Adenomas / Pituitary Diseases	1
Not Available	Completed	Treatment	Total Hip Replacement	1
Not Available	Recruiting	Basic Science	Borderline Personality Disorder (BPD) / PTSD	1
Not Available	Recruiting	Prevention	Post Traumatic Stress Disorder (PTSD)	1
Not Available	Recruiting	Treatment	Atopic Dermatitis (AD)	1
Not Available	Recruiting	Treatment	Fatty Acids, Nonesterified / Hydrocortisone / Hypopituitarism / Insulin Sensitivity / Lipids	1
Not Available	Recruiting	Treatment	Intussusception	1
Not Available	Recruiting	Treatment	Plantar fascial fibromatosis	1
Not Available	Recruiting	Treatment	Shock, Septic	1
Not Available	Suspended	Not Available	Some Studies Shows That the Steroid Can Reduce the Injury of the I/R of the Liver	1
Not Available	Terminated	Not Available	Nonvalvular Atrial Fibrillation	1
Not Available	Terminated	Prevention	Brain Death	1
Not Available	Terminated	Treatment	Necrotizing Enterocolitis	1
Not Available	Terminated	Treatment	Posttraumatic Stress Disorders	1
Not Available	Unknown Status	Prevention	Posttraumatic Stress Disorders	1
Not Available	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
Not Available	Unknown Status	Treatment	Major Depressive Disorder (MDD)	1
Not Available	Unknown Status	Treatment	PTSD	1
Not Available	Withdrawn	Treatment	Post-Traumatic Stress Disorder (PTSD)	1